Description
16,61,000 equity shares of Novelix Pharmaceuticals Limited listed on BSE with effect from January 1, 2026, issued on preferential basis pursuant to warrant conversion.
Summary
BSE has listed 16,61,000 equity shares of NOVELIX PHARMACEUTICALS LIMITED (Scrip Code: 536565) with effect from January 1, 2026. These shares were issued at Rs. 20/- (Rs. 10/- face value + Rs. 10/- premium) to Promoter and Non-Promoter on preferential basis pursuant to conversion of warrants. The shares rank pari-passu with existing equity shares.
Key Points
- Total shares listed: 16,61,000 equity shares of Rs. 10/- each
- Issue price: Rs. 20/- per share (including premium of Rs. 10/-)
- Distinctive Numbers: 14480001 to 16141000
- Date of Allotment: October 23, 2025
- Effective trading date: January 1, 2026
- ISIN: INE314I01036
- Shares rank pari-passu with existing equity shares
Regulatory Changes
No regulatory changes introduced by this circular.
Compliance Requirements
Trading members must note the new securities available for trading from January 1, 2026, subject to lock-in restrictions.
Important Dates
- Date of Allotment: October 23, 2025
- Trading Commencement: January 1, 2026
- Lock-in Expiry (5,36,000 shares): July 31, 2026 (Dist. Nos. 15605001 to 16141000)
- Lock-in Expiry (11,25,000 shares): July 31, 2027 (Dist. Nos. 14480001 to 15605000)
Impact Assessment
Limited market impact expected as:
- This is a routine listing following warrant conversion
- Significant lock-in periods apply: 11,25,000 shares locked until July 2027 and 5,36,000 shares locked until July 2026
- Shares issued on preferential basis to Promoter and Non-Promoter groups
- Total dilution represents additional capital raised through warrant conversion mechanism
Impact Justification
Routine listing of preferential shares after warrant conversion with limited market impact due to lock-in requirements